Dr. Rohit Bhargava calls attention to the fact that invasive lobular cancer is the most common subtype of breast cancer and how its significant clinical and pathologic characteristics differ from IBC-NST.
Dr. Matthew Covington discusses the challenges of imaging invasive lobular carcinoma and how, ultimately, the intricacies of its infiltrative, 'single file' growth pattern may impact patient care and lead to worse patient outcomes.
Dr. Rebecca Shatsky focuses on ILC’s unique characteristics, its under-representation in clinical trials and highlights that the evaluation and treatment plan for ILC may need to differ from other breast cancer subtypes.
Dr. Rita Mukhtar recognizes the challenges inherent in ILC surgery, requiring strategic and informed approaches to ensure optimal patient outcomes.
Interviewed by Dr. Linda Chu as part of RSNA’s Radiology Podcast series, Drs. Matthew Covington and Regina Rosenthal discuss the challenges in diagnosing and treating invasive lobular carcinoma of the breast. They explore imaging difficulties, unique metastatic patterns, and strategies for improving detection and patient case. Sponsored by GE HealthCare, Medical Affairs.
Dr. Rohit Bhargava reviews the National Cancer Institute’s definition of heterogeneity, classifies its different types, and explains how pathologists assess this molecular data.
Dr. Jane Meisel discusses how heterogeneity adds to the complexity of disease, bringing significant challenges to clinicians, in addition to reviewing the impact of heterogeneity on solid tumors and highlighting the prevalence of phenotypic discordance between a primary lesion and metastatic sites in breast cancer.
Drs. Carlos Barrios and Adam Brufsky dsicuss tumor heterogeneity as a barrier to personalized or precision medicine. Their dialogue reviews the current benefits, and limitations, of diagnostic options including (but not limited to) single tumor biopsy, liquid biopsy, radiomics, and positron emission tomography.
Dr. Linda Chu, host of RSNA’s Radiology Podcast series, speaks with Drs. Jana Ivanidze and Rajiv Maggee about how molecular imaging is transforming the diagnosis and management of breast cancer brain metastases, with an emphasis on precision and personalized care. Their discussion highlights emerging tools such as advanced PET techniques and liquid biopsy that support earlier detection, guide treatment planning, and shape the future of neuro-oncology.
GE HealthCare does not recommend or endorse the use of its products outside of the FDA approved Full Prescribing Information. Further, the information contained here should not be considered medical advice or guidelines and is intended to be nonpromotional. This information is for a US audience only. It is not intended to replace individual medical judgement or consultation with an appropriate medical professional
MedPDx-00364 August 2024.
